7 results about "Palonosetron" patented technology

Provided herein are novel ready-to-use formulations containing fosaprepitant and palonosetron, methods of preparing, and methods of using the same.

The present invention relates to the field of pharmaceutical technology, and particularly provided are a lyophilized formulation, and a preparation method therefor and the use thereof. The lyophilized formulation comprises fosaprepitant or a pharmaceutically acceptable salt thereof and human serum albumin, wherein the weight ratio of fosaprepitant or a pharmaceutically acceptable salt thereof to human serum albumin is 1:0.2 to 1:2. The lyophilized formulation may further comprise palonosetron or a pharmaceutically acceptable salt thereof, a lyophilization excipient and a pH adjuster.

The application belongs to the technical field of medicine extraction and medicine detection, and discloses a detection method of related substances in palonosetron-containing fat emulsion injection. Methanol is used as a main demulsifier, and a sodium dihydrogen phosphate buffer salt solution with a suitable ionic strength is used for assistance, so that full demulsification is realized under the premise of not introducing a third organic phase; a water bath evaporation and redissolution method is used to enrich target components in the solution after demulsification, so that good chromatographic behavior and complete recovery of the target components are ensured, and the detection sensitivity is effectively improved. The palonosetron and related impurities have good separation degree, the method is simple to operate, accurate to measure, and strong in specificity, and is suitable for the determination of palonosetron related substances in rolapitant palonosetron fat emulsion.

The present application belongs to the technical field of medicine, and particularly relates to a palonosetron transdermal patch and a preparation method thereof. The transdermal patch is composed of a backing layer, a drug-loaded pressure-sensitive adhesive layer and an anti-adhesion layer. The drug-loaded pressure-sensitive adhesive layer comprises palonosetron free base, pressure-sensitive adhesive, antioxidant and transdermal absorption promoter. The palonosetron free base accounts for 5% to 20% of the total weight, preferably 5% to 15%; the antioxidant accounts for 0.01% to 0.1% of the total weight; the transdermal absorption promoter accounts for 5% to 10% of the total weight; and the pressure-sensitive adhesive accounts for 74.9% to 89.99%. The palonosetron transdermal patch provided by the present application uses mixed pressure-sensitive adhesive of different groups to improve its adhesion and stability, and can realize slow release of palonosetron free base within 7 days.

The precise centrifugal separator comprises a mixing box, the lower end of the mixing box is fixedly connected with a collecting hopper, the lower end of the collecting hopper is fixedly connected with a separating box, the upper end of the mixing box is provided with a driving motor, the output end of the driving motor is fixedly connected with a rotating rod, and the rotating rod is fixedly connected with a rotating shaft. The precise centrifugal separator comprises a mixing box and a rotating rod, the rotating rod is rotatably connected with the mixing box, the outer side of the rotating rod is fixedly connected with a spiral blade, and the spiral blade is arranged in an inner cavity of the mixing box. According to the levoparoxol separation device, the filter screen is arranged, so that a levoparoxol mixture attached to the upper end of the filter screen can be stirred, the problem that the filter effect is reduced due to the fact that filter holes of the filter screen are blocked by particle impurities can be effectively prevented, and the filtered levoparoxol mixture falls into a separation box through a collection hopper to realize separation of levoparoxol.

A preparation system of the palonosetron sustained-release microspheres comprises palonosetron or salt derivatives thereof, an organic solvent, a polymer sustained-release material, an emulsifier, a pH regulator and a freeze-drying protective additive, and the palonosetron sustained-release microspheres are characterized in that D90 of the palonosetron sustained-release microspheres is 15-40 [mu] m, the polymer sustained-release material is a lactide-glycolide copolymer, and D90 of the palonosetron sustained-release microspheres is 1-10 [mu] m. The molar ratio of polylactic acid to polyglycolic acid in the lactide-glycolide copolymer is (40-60): (40-60), and the weight-average molecular weight of the lactide-glycolide copolymer is 7-38 kDa. The palonosetron sustained-release microsphere provided by the invention is high in drug loading capacity and encapsulation efficiency, good in 7-day sustained-release effect, obvious in vomiting stopping effect and high in bioavailability.

Provided herein are novel ready-to-use formulations containing fosaprepitant and palonosetron, methods of preparing, and methods of using the same.